Testing whether an herbal product can reduce gum inflammation when used alongside standard periodontal treatment

ISRCTN ISRCTN10262904
DOI https://doi.org/10.1186/ISRCTN10262904
Sponsor University of Niš - Faculty of Medicine
Funder Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja
Submission date
23/01/2026
Registration date
20/02/2026
Last edited
20/02/2026
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Oral Health
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
Control (SRP) group- patients with periodontitis who received SRP treatment - by ultrasonic scaler Woodpecker and curettage with curettage of periodontal pockets for five consecutive days. The experimental group - patients with periodontitis who received local phytotherapy after causal periodontal therapy.

Who can participate?
Adults who are systemically healthy and diagnosed with moderate periodontitis (Stage II, Grade A) may participate. Participants must have at least 24 natural teeth and radiographic evidence of periodontal bone loss. Individuals who smoke, consume alcohol, have systemic diseases (such as diabetes or immune disorders), or are undergoing systemic drug therapies affecting the gums are not eligible.

What does the study involve?
Participants are randomly assigned to one of two groups. One group receives standard SRP therapy only, while the other receives SRP plus a topical application of the polyherbal phytopreparation. Treatment is performed over five consecutive days. Clinical examinations are carried out before treatment and one month later. Gingival cell samples are collected for microscopic analysis.

What are the possible benefits and risks of participating?
Participants may experience improvement in gingival inflammation and periodontal health. No side effects were observed during the study period. However, mild local reactions are possible, as with any topical dental treatment.

Where is the study run from?
The study is conducted at the Clinic of Dentistry, Faculty of Medicine, University of Niš, Serbia.

When is the study starting and how long is it expected to run for?
Each participant is involved in the study for approximately one month, including treatment and follow-up. The exact start date 18/10/2020, and it is expected to run for four years.

Who is funding the study?
This work was supported by the Ministry of Education, Science, and Technological Development of the Republic of Serbia. The funders had no role in the design of the study; the collection, analysis, or interpretation of data; the writing of the manuscript; or the decision to publish the results.

Who is the main contact?
The study is conducted under the supervision of the Clinic of Dentistry, Faculty of Medicine, University of Niš, Serbia. Principal investigator was dr Milica Petrović, Assistant Professor (milica.petrovic@medfak.ni.ac.rs)

Contact information

Prof Milica Petrović
Principal investigator

Cara Dušana 28/7
Niš
18000
Serbia

ORCiD logoORCID ID 0000-0001-6564-5131
Phone +381 642373966
Email milica.petrovic@medfak.ni.ac.rs
Prof Bojana Miladinović
Scientific

Blagoja Parovića 16
18000
18000
Serbia

ORCiD logoORCID ID 0000-0003-2880-6519
Phone +381 691045097
Email bojana.miladinovic@medfak.ni.ac.rs
Prof Dušanka Kitić
Public

Timočka 11
Niš
18000
Serbia

ORCiD logoORCID ID 0000-0001-8551-274X
Phone +381 62328036
Email dusanka.kitic@medfak.ni.ac.rs
Prof Ljiljana Kesić
Principal investigator

Železničkih Kolonija 3a
Niš
18000
Serbia

ORCiD logoORCID ID 0000-0003-0463-3246
Phone +381 642373966
Email kesic.ljiljanaa@gmail.com

Study information

Primary study designInterventional
AllocationRandomized controlled trial
MaskingBlinded (masking used)
ControlActive
AssignmentParallel
PurposeSupportive care, Treatment
Participant information sheet 48895 Participant_Information_Sheet.pdf
Scientific titleEfficacy of a topical polyherbal phytopreparation as an adjunct to scaling and root planing therapy in patients with periodontitis: a randomized controlled clinical study
Study acronymPHYTO-PERIO Trial
Study objectives The primary objective of this randomized controlled clinical study was to evaluate the clinical efficacy of a topical polyherbal phytopreparation (Tinctura paradentoica®, https://www.mocbilja.rs/proizvod/kapi-za-jacanje-desni/) as an adjunct to scaling and root planing (SRP) in patients with stage II, grade A periodontitis, by assessing changes in gingival inflammation (gingival index) and periodontal pocket depth. Secondary objectives included evaluation of cytomorphometric changes in gingival epithelial cells following treatment and exploration of potential mechanistic support using HPLC-guided in silico molecular docking (COX-1/COX-2) and ADME/Tox profiling.
Ethics approval(s)

Approved 23/07/2020, Ethics Committee of Faculty of medicine, University of Niš (Dr Zoran Djindjić Ave 81, Niš, 18000, Serbia; +381 184226644; pravna.sluzba@medfak.ni.ac.rs), ref: 12-6422-2/7

Health condition(s) or problem(s) studiedThe efficacy of a polyherbal phytopreparation as an adjunctive therapy to scaling and root planing in patients with periodontitis.
InterventionThis study is designed as a randomized controlled clinical trial including 80 adults diagnosed with stage II, grade A periodontitis. After baseline assessment, participants are randomly allocated in a 1:1 ratio into two groups using computer-generated randomization with equal block sizes. Allocation concealment is ensured by sequentially numbered, opaque, sealed envelopes prepared by an independent examiner not involved in enrollment or outcome assessment. Participants and the recruiting investigator remain blinded to group assignment.

Control group(SRP): Participants receive causal periodontal therapy consisting of ultrasonic scaling, root planing, polishing and curettage of periodontal pockets performed over five consecutive days (SRP using an ultrasonic scaler and Gracey curettes). Standardized oral hygiene instructions are provided.

Experimental group (SRP + phytotherapy): Participants receive the same SRP protocol and oral hygiene instructions as the control arm, followed by topical subgingival application of the polyherbal phytopreparation Tinctura paradentoica®. The intervention is administered locally using a sterile syringe with a 23-gauge needle (110° angulation). A dose of 0.1 mL per periodontal pocket is applied subgingivally under cotton roll isolation for 2 minutes per quadrant, according to the study protocol.

Clinical outcomes (gingival index and periodontal pocket depth) are assessed at baseline and at one month after therapy initiation by a single calibrated examiner blinded to treatment allocation. Cytomorphometric analysis of gingival epithelial cells is performed using exfoliative cytology samples collected at baseline and at one month. In addition, the study includes an exploratory HPLC-guided in silico analysis (molecular docking to COX-1/COX-2 and ADME/Tox profiling of identified phenolic constituents) to support mechanistic plausibility.
Intervention typeSupplement
Primary outcome measure(s)
  1. Gingival inflammation, Gingival Index (GI) measured using the Löe and Silness Gingival Index at baseline (pre-treatment), five days and 1 month after therapy initiation
Key secondary outcome measure(s)
  1. Periodontal pocket depth (PPD, mm) at baseline (pre-treatment) and 1 month after therapy initiation. measured using a manual WHO periodontal probe at baseline (pre-treatment) and 1 month after therapy initiation
  2. Nuclear area (µm²) measured using cytomorphometric analysis of exfoliative gingival epithelial cells (light microscopy/image analysis) at baseline and 1 month after therapy initiation
  3. Nuclear perimeter (µm) measured using cytomorphometric analysis of exfoliative gingival epithelial cells (light microscopy/image analysis) at baseline and 1 month after therapy initiation
  4. Ferret’s diameter (µm) measured using cytomorphometric analysis of exfoliative gingival epithelial cells (light microscopy/image analysis) at baseline and 1 month after therapy initiation
  5. Integrated optical density (IntDen) measured using densitometric cytomorphometric analysis of exfoliative gingival epithelial cells (image analysis software) at baseline and 1 month after therapy initiation
  6. Binding affinity to COX-2 measured using molecular docking (in silico docking score) at in silico analysis performed after identification of phytochemicals by HPLC-DAD
  7. Binding affinity to COX-1 measured using molecular docking (in silico docking score) at in silico analysisperformed after identification of phytochemicals by HPLC-DAD
  8. ADME profile measured using in silico pharmacokinetic prediction (SwissADME or equivalent ADME prediction tool) at in silico analysis performed after identification of phytochemicals by HPLC-DAD
  9. Toxicological profile measured using in silico toxicity prediction (ProTox-II or equivalent toxicity prediction tool) at in silico analysis performed after identification of phytochemicals by HPLC-DAD
Completion date18/10/2024

Eligibility

Participant type(s)
Age groupMixed
Lower age limit18 Years
Upper age limit65 Years
SexAll
Target sample size at registration150
Total final enrolment98
Key inclusion criteria1. Adults aged 18 to 65 years.
2. Individuals diagnosed with periodontitis based on medical history and clinical evaluation.
3. Presence of at least 24 natural teeth.
4. Radiographic evidence of bone loss.
5. Periodontal status determined using the 2018 classification of periodontal diseases and conditions.
6. Diagnosis of periodontitis confirmed by either interdental clinical attachment loss at two or more non‑adjacent teeth, or buccal/oral clinical attachment loss of 3 mm or more together with periodontal pocket depth of 3 mm or more at two or more teeth.
7. Individuals not meeting the above diagnostic criteria were considered periodontally healthy and therefore not included.
Key exclusion criteria1. A history of alcohol consumption
2. Tobacco use in any form (past or present)
3. A medical history of anemia
4. Diabetes
5. Hepatitis
6. Tuberculosis
7. AIDS
8. Leukemia
9. Other systemic or hormonal disorders linked to gingival manifestations
10. Those who were undergoing or had previously undergone treatment with systemic hormonal therapy, contraceptive usage, corticosteroids, immunosuppressants, radiation therapy, or chemotherapy before the study started
Date of first enrolment18/10/2020
Date of final enrolment18/08/2024

Locations

Countries of recruitment

  • Serbia

Study participating centres

Dentistry Clinic, Department of Oral medicine and periodontology, Faculty of Medicine, University of Niš
Bulevar Dr Zorana Djindjica 52
Niš
18000
Serbia
Pathology Center of the Clinical Center Niš
Bulevar Dr Zorana Djindjica 48
Niš
18000
Serbia
Faculty of Medicine, Department of Pharmacy University of Niš
Bulevar Dr Zorana Djindjica 81
Niš
18000
Serbia

Results and Publications

Individual participant data (IPD) Intention to shareNo

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Other files Participant flow diagram 26/01/2026 No No
Other files Informed Consent Form 28/01/2026 No No
Other files Schedule of Enrolment, Interventions, and Assessments 28/01/2026 No No
Participant information sheet 28/01/2026 No Yes
Protocol file 28/01/2026 No No
Statistical Analysis Plan 28/01/2026 No No

Additional files

48895 Particpant flow diagram.pdf
Participant flow diagram
48895 Participant_Information_Sheet.pdf
Participant information sheet
48895 Schedule of Enrolment, Interventions, and Assessments SPIRIT_Schedule_Addendum.pdf
Schedule of Enrolment, Interventions, and Assessments
48895 Informed_Consent_Form.pdf
Informed Consent Form
48895 Clinical Study Protocol.pdf
Protocol file
48895 Statistical Analysis Plan (SAP).pdf
Statistical Analysis Plan

Editorial Notes

26/01/2026: Trial's existence confirmed by Ethics Committee of Faculty of medicine, University of Niš.